We have examined the influence of glutamate on cortical brain-derived neurotrophic factor (BDNF) expression using in situ hybridization and immunohistochemistry. Kainic acid (KA) produced an upregulation of hippocampal and neocortical BDNF mRNA as well as BDNF protein that was blocked by a non-NMDA antagonist, 6,7-dinitroquinoxaline-2,3-dione (DNQX), but was not affected by the NMDA antagonist 2-amino-7-phosphonoheptanoic acid (AP7). Basal levels of BDNF mRNA were not affected by NMDA, DNQX, or AP7 treatment.
BDNF protein was also increased after kainate exposure with a spatial and temporal course distinct from that seen for the expression of BDNF mRNA. A dramatic shift in BDNF immunoreactivity (-IR) was observed from intracellular compartments to the neuropil surrounding CA3 pyramidal cells 2-3 hr after KA exposure. This shift in localization of BDNF-IR suggests a constitutive release of BDNF at the level of the cell body and dendrites.
Moreover, we have localized mRNAs for full-length and truncated f&R, to a coincident population of neurons and glia. These data suggest the neurons that produce BDNF also express components necessary for a biological response to the same neurotrophic factor. The present study also demonstrates increased BDNF-IR in the mossy fiber terminal zone of hippocampus after exposure to KA, as well as an increase in f&B mRNA, and provides evidence of local release of this neurotrophin into the surrounding neuropil where it would be available for local utilization.
The synthesis and putative release of BDNF from somatic and/or dendritic sites within the hippocampus provide evidence of a potential autocrine or paracrine role for BDNF, and establish a local source of trophic support for the maintenance of synaptic plasticity and anatomic reorganization in the mature nervous system. [Key words: neurotrophin, NGF, brain-derived neurotrophic factor, kainic acid, hippocampus, trk B, sprouting, epilep-SYI The role of neurotrophic factors in the development and maintenance of neuronal architecture has attracted a great deal of interest with the recent cloning of several members of the NGF family. The neurotrophin family members NGF, brain-derived neurotrophic factor (BDNF) (Leibrock et al., 1989 ) and neurotrophin-3 (NT3) (Ernfors et al., 1990a; Hohn et al., 1990; Kaisho et al., 1990; Maisonpierre et al., 1990; Rosenthal et al., 1990) are highly conserved and share greater than 50% primary sequence homology (for reviews, see Barde, 1990; Thoenen, 199 1) . These neurotrophins affect the survival and differentiation of overlapping yet distinct populations of central and peripheral neurons (Thoenen and Barde, 1980; Levi-Montalcini, 1987; Barde, 1989; Lindsay et al., 199 1) . Because of their effects upon populations of neurons in the CNS, it has been suggested that a lack of trophic factors may play a role in neurodegenerative diseases (Mattson, 1989; Wainer, 1989; Lindsay et al., 199 1; Phillips et al., 199 1) . For example, neuronal degeneration caused by lesions of various cholinergic projections to the hippocampus can be somewhat ameliorated by the administration of NGF (Hefti, 1986; Williams et al., 1986; Koliatsos et al., 1990; Stromberg et al., 1990) suggesting that changes in the availability of target-derived trophic factors may play a role in the remodeling of CNS connections. BDNF has attracted considerable interest because it is the most widely distributed neurotrophin family member in the brain (Ernfors et al., 1990b; Hofer et al., 1990; Phillips et al., 1990; Wetmore et al., 1990) and has been reported to increase the survival and expression of the neurotransmitter phenotype of cholinergic as well as dopaminergic neurons (Alderson et al., 1990; Hyman et al., 199 1; Kntisel et al., 199 1) . Additionally, it has been demonstrated that multiple seizure episodes as well as injury can effect anatomical as well as functional changes in neuronal connectivity including long-term potentiation, mossy fiber sprouting, and synaptic reorganization within the hippocampus (Cotman et al., 1984; Cotman, 1985; Sutula et al., 1989; Cavazos et al., 1991; see BenAri and Represa, 1990; Geddes et al., 1990) . Such alterations may well also involve altered expression of neurotrophic factors (Patterson et al., 1992; see Gall, 1992) .
Glutamate is the major excitatory amino acid transmitter utilized in the brain (Kandel et al., 199 1) . Effects of glutamate are mediated through at least three receptor subtypes that have been classified pharmacologically with respect to their most selective ligands: NMDA, kainate, and quisqualate or ol-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) (Watkins and Evans, 198 1; Watkins et al., 1990) . Ligand binding autoradiography has shown that the highest density of NMDA binding sites in brain is found in CA1 of the hippocampus (Monaghan et al., 1983) while lower densities have been reported in CA3 and in the mossy fiber termination zone (Berger and Ben-Ari, 1983; Monaghan et al., 1983; Represa et al., 1987) (for review, see Cotman et al., 1987) . In contrast, the highest densities of kainate receptor binding are found in hippocampal regions that contain low NMDA receptor density, such as the stratum lucidum and the zone of mossy fiber termination. This high receptor density correlates with the extreme sensitivity of cells in these areas to kainic acid (KA) (Nadler et al., 1978) . Moreover, mRNAs for subunits of non-NMDA receptors are most highly expressed in pyramidal cells in CA l-CA3 and granule cells of the dentate gyrus (Boulter et al., 1990) . Thus, excitatory amino acid receptors comprise a heterogeneous group of proteins that provide a basis for variable and dynamic cellular responses to a common neurotransmitter (Cotman et al., 1987) .
Excitatory amino acids may produce neurotoxic effects (Simon et al., 1984; Wieloch, 1985; Mattson, 1989; Choi, 1990) and their receptors are altered in some neurodegenerative diseases (Geddes et al., 1985; Greenamyre et al., 1985) . However, stimulation of excitatory amino acid receptors may also play a modulatory role in the expression of trophic factor mRNA (Isackson et al., 199 1; for review, see Gall, 1992) suggesting that excitatory amino acids may have both destructive and constructive effects on neuronal architecture. In this regard, treatment with intracerebral (Ballarin et al., 1991; Gall et al., 1991) as well as systemic (Zafra et al., 1990; Dugich-Djordjevic et al., 1992) glutamate analogs has been reported to upregulate levels of NGF and BDNF, but not NT3 mRNAs. Neuronal activity, particularly via excitatory amino acid receptors, results in a rapid induction of immediate-early genes (Cole et al., 1989) as well as inducing synaptic remodeling (Brooks et al., 199 1; Geinisman et al., 1992) and sprouting (Geddes et al., 1985; Cornell-Bell et al., 1990) . Additionally, limbic seizures produce hippocampal cell loss (Mattson, 1989; Choi, 1990) as well as increase levels of NGF (Gall and Isackson, 1989) and alter excitatory amino acid receptor expression (Gall et al., 1990; see Gall, 1992) .
In the present study we have investigated the pharmacology of LA-induced alterations in cortical BDNF expression in vivo, and the tonic influence of glutamate on the basal expression of BDNF mRNA. The complementary use of in situ hybridization and immunohistochemical techniques has allowed us to examine the anatomical distribution of cells that are affected by these pharmacological manipulations and to determine which of these cells also may express mRNA for trkB, a component of the BDNF receptor. Using anti-peptide antibodies specific for BDNF (Wetmore et al., 199 1, 1992) we were able to determine whether alterations in BDNF mRNA resulted in concomitant changes in protein expression, and to demonstrate the putative local release of BDNF from neurons within hippocampal subfields after KA administration. These data suggest that, unlike the storage and release of neuropeptides, which are confined to axon terminals (Elde et al., 1978 ) the release of neurotrophic factors may occur directly from somatic and/or dendritic sites and may play a role in the maintenance of local circuitry within the hippocampus by autocrine as well as paracrine mechanisms of action. adjusted to 7.4 with 0.2 N HCl, and diluted to stated concentrations with saline.
Treatment of animals and tissue preparation. Forty female SpragueDawley rats (150-200 gm) were used in the in situ hybridization studies, and 24 rats were used in immunohistochemical studies. KA (12 mg/kg) was administered intraperitoneally while all other compounds were administered intracerebroventricularly (10, pi/injection) with a Hamilton syringe. For intracerebroventricular administration animals were anesthetized with halothane and mounted in a stereotaxic frame, and the skull was exposed and holes were drilled with stereotaxic guidance (AP 0.3, L 1.4, V 4.1 from bregma) of sufficient size to accommodate the injection cannula. Animals were divided into 10 treatment groups, each group comprising four rats: group I, KA; II, AP7; III, DNQX; IV, AP7 + KA: V. DNOX + KA: VI. vehicle + KA: VII. vehicle: VIII. NMDA: IX, NMDA +.AP7; X, 'untreated. Halothane treatment alone had no significant effect on BDNF mRNA expression in hippocampus (data not shown). When two compounds were used, the second was injected 30 min after the first. For in situ hybridization studies, animals were decapitated and brains removed and frozen 5.5-6 hr after last treatment. Cryostat sections (14 pm) of tissue were thawed onto ProbeOn slides (Fischer) and stored at -20°C prior to hybridization.
In situ hybridization. Oligonucleotide probes complementary to BDNF (Leibrock et al., 1989 ) (bases 250-298) NGF (Whittemore et al., 1988) (bases 374-422) NT3 (bases 827-874) and trkB (Middlemas et al., 199 1) (bases 2576-2617 and 723-767) were synthesized (Scandinavian Gene Synthesis) and 3' end labeled with IS-dATP. A sequence complementary to the rat NGF receptor (Radeke et al., 1987) (873-920) mRNA with comparable GC content and a sense oligonucleotide probe corresponding to the NGF probe served as controls. Procedures for in situ hybridization were as described (Dagerlind et al., 1992) . Sections were hybridized with specific and control probes for 16 hr at 42°C. Slides were either exposed to film for 4-8 weeks or dipped in Kodak NTB2 emulsion, diluted 1: 1 in distilled water, and exposed for lo-12 weeks at -20°C.
Immunohistochemistry. Rats from groups I, II, V-VII, and X as detailed above (150 gm female, Sprague-Dawley, ALAB, Sweden) were anesthetized with sodium pentobarbital (Mebumal, 40 mg/kg, i.p.) and perfused via the ascending aorta with 50 ml of Ca2+-free Tyrode's solution followed by 50 ml of formalin-picric acid mixture (4% paraformaldehyde, 0.4% picric acid in 0.16 M phosphate buffer; pH 6.9). Brains were removed and processed for immunohistochemistry as previously described using antibodies raised against synthetic peptides derived from BDNF and pro-BDNF amino acid sequences (Wetmore et al., 1991 . Tissues were examined and photographed using epifluorescence microscopy (Nikon-Microphot).
Ouantification and evaluation ofcell labelina. For evaluation of mRNA signals, measurements were performed on-two nonadjacent sections from each brain that had been hybridized, dipped in emulsion, developed, and counterstained with cresyl violet. Sections were analyzed with an image analysis system consisting of a Nikon Microphot microscope, a DAGE-MT1 CCD 72 camera linked to an Apple computer containing a Quick Capture frame grabber card, and the IMAGE program (kindly supplied by Dr. Wayne Rasband, NIMH). For quantification each section was digitized by averaging 16 frames and areas to be measured were outlined interactively, as were background areas immediately adjacent to the area of interest. Background measures were subtracted from mean optical density measures for areas of interest. Groups I and VI as well as VII and X were not statistically different from each other @ > 0.05 Student's t test) and were therefore combined for subsequent analysis. Statistical analysis was performed using a one-way ANOVA with post hoc Bonferroni multiple comparison test where appropriate.
For immunohistochemical evaluation of BDNF immunoreactivity (-IR) after control, KA, and DNQX + KA treatments, brains from six to eight rats from time points 2.5, 6, 12, and 18 hr posttreatment were evaluated.
Results

Materials and Methods
Compounds. KA (Sigma) was dissolved in saline (12 mgml), 2-amino-7-phosphonoheptanoic acid (AP7; 50 nmol/pl), 6,7-dinitroquinoxaline-2,3-dione (DNQX; 2 nmol/& and NMDA (0.1 nmol/pl) (Research Biochemicals Inc., Natick, MA) all were dissolved in 1 N NaOH, pH Specificity controls Oligonucleotide probes used in these studies labeled bands of appropriate size for BDNF [4.0 and 1.6 kilobases (kb)] on Northern analysis of total RNA from adult rat brain (data not shown). To illustrate that the KA-mediated upregulation in mentary to the low-affinity NGF receptor, which is not normally expressed by neurons in the rat hippocampus. The BDNF-specific peptide antibodies used in the present studies have been previously characterized (Wetmore et al., 199 1, 1993) . All immunostaining was blocked with preabsorption of the antibody with the cognate peptide, as previously described. Upregulation of pro-BDNF-IR was detected in the cytoplasm of pyramidal and granule cells; however, no shift of immunoreactivity was detected in the surrounding neuropil with these antibodies as was noted with the antisera raised against the mature BDNF peptides.
Behavioral observations Animals were observed for immediate (5-30 min postadministration) and delayed (30-90 min postadministration) reaction to the pharmacologic agent (Table 1) . In each treatment category, most animals exhibited behavioral manifestations consistent with the pharmacological agent used (i.e., seizures after KA and NMDA treatment, lethargy after DNQX and AP7 treatment, no behavioral difference among the vehicle-treated and normal control animals). Such behavioral monitoring served to confirm the efficacy of the selected dosage of drug, as well as to eliminate from this study animals appearing less sensitive or unresponsive to a given drug.
Regulation of BDNF mRNA Following KA exposure, expression of BDNF mRNA was markedly increased in neurons throughout most cortical areas (Fig.  1B) with highest expression in the granule and pyramidal cell layers of hippocampus (CAl: F = 7.91, p < 0.0001; CA2: F = 10.52, p < 0.0001; CA3a+b: F = 8.42, p < 0.0001; CA3c: F = 9.99, p < 0.0001; dentate: F = 11.59, p < O.OOOl), and in both superficial and deep pyramidal cell layers of neocortex (F = 21.6, p < 0.0001) and in the amygdala. More specifically, very dense labeling could be detected over the large pyramidal cells in areas CA2 and CA3 and with smaller cells clearly visible in CA1 and in the dentate granule cell layer. Neocortical areas were all labeled without obvious regional alterations, with heaviest labeling in layers II/III and VI. The kainate-induced upregulation in BDNF mRNA was blocked in most regions by prior treatment of the animals with DNQX ( Fig. 1C) (CAl, p = 0.028; CA2, p = 0.065; CA3a-t b, p = 0.085; CA3c,p = 0.034; dentate, p = 0.014; cortex, p < 0.001) (Fig. lC) , a competitive kainate receptor antagonist, but not with AP7 ( Fig. 1D ) (all regions p > 0.05), a competitive NMDA receptor antagonist. Moreover, no change in basal BDNF expression was observed after DNQX (Fig. lE) , AP7 ( Localization of trkB mRNA to neurons that also express BDNF mRNA Expression of mRNA for a truncated transcript of trkB (trkB,,,,,) was detected in most, if not all, cells of hippocampus (Fig. 2B ) and other brain regions (C. Wetmore, L. Olson, and A. I. Bean, unpublished observations), while full-length transcripts of trkB appeared to be confined to neurons ( Fig. 2A) . Based upon examination of consecutive slides hybridized with oligonucleotide probes complementary to BDNF mRNA, it appears that most hippocampal pyramidal cells that express BDNF mRNA and protein also express trkB mRNA. Expression of trkB mRNA was not significantly affected by KA exposure; however, trkB,,,,, mRNA was increased 6 hr after KA treatment (not shown), though not as dramatically as detected for BDNF mRNA.
Evaluation of immunohistochemical localization of BDNF Levels of BDNF-IR were visually rated on a scale of relative intensity [ranging from barely detectable (+) to very strong (+ + + + +)], with basal levels of BDNF expression being set at "++" throughout all hippocampal fields except CA2, where basal levels of immunoreactivity were higher and set at "+ + +." Values listed in Table 2 were obtained from evaluation of approximately 30 tissue sections obtained from six to eight rats per time point. 
Regulation and distribution of BDNF-IR after k?A treatment
While a significant, kainate-induced increase in BDNF mRNA was detected throughout hippocampal and other cortical areas, this change in mRNA was not paralleled by alterations of equal magnitude and distribution of BDNF protein (Table 2) . Specifically, an initial diminution of BDNF-IR in pyramidal cell cytoplasmic compartments was noted with concomitant in- crease in BDNF-IR in the surrounding neuropil of the mossy fiber terminal zones of CA3a-c (Figs. 3, 4) . A marked increase in BDNF-IR in the peripheral cytoplasm of neurons in the lateral amygdaloid nucleus was also noted shortly (2-3 hr) after kainate exposure, but without any apparent increase in immunoreactivity of surrounding parenchyma (not shown). At later time points, significant increases in BDNF-IR were detected in somata and proximal dendrites of pyramidal neurons in hippocampus (Fig. 5E ) and in piriform cortex (not shown), while more moderate alterations in BDNF-IR were detected in dentate granule cells (Fig. 3E ) and in neocortical areas. The KA-induced upregulation of BDNF mRNA and BDNF-IR was blocked by prior treatment with DNQX (Fig. 6) . No glial expression of BDNF-IR was detected in control or in KA-treated animals. Three hours. A dramatic shift in the localization of BDNF-IR was detected 2-3 hr postadministration of KA in the CA3 and the hilar region of dentate gyrus (Figs. 3, 4) where a bright zone of immunoreactivity was observed in the neuropil surrounding the faintly immunoreactive large pyramidal cells of CA3c (Fig. 4B) and extending along the pyramidal cell layer in areas CA3a+b and CA2 (Figs. 4B, 5s ). This zone of BDNF-IR was coincident with the termination zone of mossy fibers. A similar zone of immunoreactivity in the neuropil was noted in the molecular layer of dentate gyrus (Fig. 3B ). Hilar cells (Fig.  4B ) and pyramidal cells in hippocampal areas CA2 and CA3 (Fig. 5B) showed decreased cytoplasmic BDNF-IR, in marked contrast to the strongly immunofluorescent neuropil. BDNF-IR was slightly increased in CA1 neurons, though not as marked as in other hippocampal areas. Slightly decreased immunoreactivity was detected in dentate granule cell (Fig. 3) cytoplasm. Cytoplasmic BDNF-IR in the amygdala was markedly increased Figure 3 . Photomicrographs of BDNF-IR and cresyl violet-stained tissue in dentate gyrus, CA3q and hilar regions of hippocampus at various time points after KA exposure: A, control; B, 2-3 hr; C, 6 hr; D, 12 hr; E, 18 hr. Representative sections stained with cresyl violet show signs of cellular degeneration and diffusely stained nuclei (arrows) 18 hr after KA exposure (G) as compared with control (F).
in both intensity and in number ofcells labeled and was localized dendrites of the neurons in superficial layers (II/III) were more to perinuclear cytoplasm (not shown).
distinctly outlined by an increased peripheral cytoplasmic imSlight changes in BDNF-IR were noted in neurons in the munofluorescence, similar in nature but less intense than that superficial layers of piriform cortex. The somata and proximal observed in the amygdala. Six to eight hours. BDNF-IR in dentate granule cells returned to control levels, with some very bright, scattered cells (Fig. 3C) . Neuropil surrounding dentate granule cells was darker than seen at 3 hr. The highest levels of BDNF-IR in CA1 and CA2 were detected at this time point, with an increase in cytoplasmic BDNF-IR in pyramidal cells in CA3 (Fig. 5C ) and hilar areas (Fig. 4C) , including distinct basal dendrites on neurons in CA3c, which were strongly immunolabeled (Fig. 4c ). An area of BDNF-IR along the inner aspect of CA3, extending into the hilus, coincident with the terminal zone of mossy fibers, was readily apparent and the immunoreactivity appeared weaker and more particulate than at 3 hr (Fig. 5C) . Neurons in the superficial layers of piriform cortex showed an increase in BDNF-IR, with a slight darkening of the neuropil in deeper layers.
Twelve hours. BDNF-IR in dentate granule cells appeared somewhat lower than at 6-8 hr and below control levels with faintly outlined cytoplasm visible against the darkened neuropil (Fig. 30) . Immunoreactivity in hilar cells was extremely weak or absent, other than a faint immunoreac;ivity of the neuropil in some brains. CA1 and CA2 immunolabeling was very pronounced, with a further darkening of the cells in hilar (Figs. 30,  40 ) and CA2-3 regions (Fig. 5D ) to below control levels. Some bright, scattered pyramidal cells were detected in areas CA2 and CA3 (Fig. 5D ), though there were many more weakly immunoreactive cells as well as dark patches throughout CA3 and extending into the hilar region (Figs. 40, 5D ). Neurons in superficial layers of piriform cortex were consistently immunoreactive, and strongly immunolabeled cells were easily detected scattered throughout deeper layers of the darkened neuropil. Eighteen hours. BDNF-IR in dentate granule cells was equal Finure 5. Photomicrographs of BDNF-IR and cresyl violet-stained tissue in CA2-CA3a regions ofhippocampus at various time points after KA exposure: A, control; B, 2-3 hr; C, 6 hr; D, 12 hr; E, 1% hr. Insets show high magnification of cells in CA2. Note 2-3 hr after KA exposure BDNF-IR is only faintly detected in pyramidal cell cytoplasm while a marked increase in BDNF-IR was detected in mossy fiber terminal zone (B). At 6 hr (C) BDNF-IR in CA2 pyramidal neurons (arrows) is above control levels (A), falls back to approximately control levels at 12 hr (D), and again is increased at 18 hr, most markedly in CA2 (E). Representative sections stained with cresyl violet show marked degeneration of cell bodies and distortion of the architecture of pyramidal cell layer; shrunken, pyknotic somata; and increased vacuolization of surrounding neuropil 18 hr after KA exposure (G) as compared with control (F). Fig. 4 ) at 2-3 hr after saline treated control rats (A), 2-3 hr after KA treatment (B), and 2-3 hr after DNQX and KA treatment (C) (DNQX given 30 min prior to KA treatment). Note increased BDNF-IR in mossy fiber terminal zone in CA3 (B) at 2-3 hr after KA exposure, which was essentially blocked by prior treatment with the non-NMDA antagonist DNQX (C).
to, or slightly above, control levels (Fig. 3E) . The outline of dark hilar cells could be detected in the slightly increased background immunostaining of the neuropil (Figs. 3, 4E ). Many neurons in CA3 and CA1 did not contain any BDNF-IR (Fig.  5E ) and were pale and diffuse with pyknotic or absent nuclei on cresyl violet-stained sections (Figs. 4F,G; 5F,G). The remaining pyramidal cells in CA2 and scattered cells in CA 1 and CA3 were brightly immunoreactive with distinct nuclei (Fig.  5E ). Pyramidal cell somata and dendrites in CA2 were markedly immunoreactive and did not demonstrate detectable cytopathology (Fig. 5F ,G).
KA-induced alterations in BDNF-IR were substantially blocked by DNQX Consistent with the regulation of BDNF mRNA via non-NMDA glutamate receptors, kainate-induced increases in cytoplasmic and local release into the parenchyma of BDNF-IR were substantially blocked by prior treatment with DNQX (Fig. 6) . No increase in BDNF-IR was detected in cortical neurons of layers II and IV/V, and the striking shift of BDNF-IR from somatic compartments to the surrounding neuropil was not seen after treatment with DNQX prior to KA administration. However, there did appear to be a slight increase in BDNF-IR in the peripheral cytoplasm of pyramidal neurons of CA2 and CA3 hippocampal areas in some animals after DNQX + KA treatment (Fig. 6C) , indicating that there appeared to be some KAinduced alteration of neurotrophin protein levels despite the prior treatment with DNQX, which was not detected at the level of mRNA.
Discussion
The present data suggest that glutamate may regulate cortical BDNF expression via kainate receptors, but not NMDA receptors. Increases in BDNF mRNA expression in response to KA were antagonized by DNQX, while AP7 had no significant effect on the elevated BDNF mRNA levels. Basal BDNF mRNA expression was not altered by interruption of the tonic glutamate activity by treatment with AP7 or DNQX at doses that elicited behavioral manifestations (Table l ), yet were not noted to induce significant alterations in expression of BDNF mRNA. Alterations in BDNF protein were observed in response to KA in cortical areas with an altered temporal and spatial distribution than that noted for BDNF mRNA, including a marked shift from intracellular somatic compartments to the surrounding parenchyma and/or neuropil at early time points. Previous studies have shown that exposure to KA induces a dramatic increase in NGF and BDNF mRNA in the hippocampus (Ballarin et al., 199 1; Gall et al., 1991; Dugich-Djordjevic et al., 1992 ; for review, see Gall, 1992) . The KA-induced upregulation of neurotrophin mRNA in vitro was blocked by non-NMDA antagonists (Zafra et al., 1990) although the types of cells in which this modulation took place was not determined. In vitro, the KA-mediated upregulation of BDNF and NGF mRNA is blocked by the non-NMDA receptor antagonist 6-cyano-7-dinitroquinoxaline-2,3-dione (Zafra et al., 1990 ) while under basal conditions both NGF and BDNF mRNA appear to be regulated via NMDA receptors and not significantly affected by the non-NMDA receptor antagonist NBQX (Zafra et al., 1991) . In vivo, both NMDA and non-NMDA receptor antagonists have been reported to modulate the expression of BDNF and NGF, as determined by Northern blot and quantitative polymerase chain reaction analyses, respectively (Zafra et al., 199 1) . The results of the present study concur with the Northern blot analysis of neurotrophin mRNA levels reported by Zafra and colleagues (199 1) with respect to the non-NMDA receptor-mediated upregulation of BDNF after IL4 exposure. In addition, the present study illustrates the subpopulations of cells in which this increased expression of BDNF mRNA occurs, as well as provides novel data regarding the regulation and potential sites of local release of BDNF protein.
Alterations in basal levels of BDNF expression at the cellular level were not detected after exposure to NMDA or the NMDA antagonist AP7. Moreover, a recent study has reported that the BDNF gene contains multiple promoters, some ofwhich contain sequences that may be differentially responsive to the activation of non-NMDA receptors and can control regionally specific expression of BDNF mRNA in the brain (Timmusk et al., 1993) . Thus, inconsistencies among studies may be attributed to such differentially regulated neurotrophin transcripts and/or methodological differences (e.g., analysis of extracts of tissue homogenates as compared to the histological evaluation of alterations in expression at the cellular level). As the cellular expression of neurotrophins is heterogeneous with respect to the level and distribution of cells, it is not possible to note modest alterations in neurotrophin expression of individual cells when analyzing tissue homogenates.
KA-induced alterations in BDNF-IR were primarily detected in neurons in the hippocampus, piriform cortex, and amygdala, with a significant shift of the BDNF-IR from cellular compartments into the surrounding parenchyma and neuropil in the mossy fiber terminal zone 2-3 hr after treatment, which was substantially blocked by prior administration of DNQX. The increase in BDNF-IR after KA in the mossy fiber termination zone was observed to have a similar time course as that which has been reported for early histopathological changes of pyramidal neurons, including shrinkage of neuronal perikarya and swelling of dendrites and axon terminals (Sperk et al., 1983) . Such changes were noted 3 hr after KA lesion and were reversible (Sperk et al., 1983) . A very pronounced increase in BDNF-IR was seen in the termination zone of the mossy fibers, which are known to contain a high density ofkainate binding sites (Represa et al., 1987) . The mossy fibers originate from dentate granule cells, which show a rapid and marked increase in BDNF mRNA 30 min post-KA, and project extensively to CA3 pyramidal cells of hippocampus (Blackstad et al., 1970; Lynch et al., 1973; Gaarskjaer, 1978) . While pyramidal cells are destroyed by moderate doses of intracerebroventricularly administered KA, dentate granule cells are not (Nadler et al., 1981) . However, electron-dense degeneration of mossy fiber boutons were detected though there was not apparent damage to the cell bodies at 4 hr after intraventricular injection of KA (Nadler et al., 1981) . Interestingly, intraperitoneal administration of KA (as used in the present study) also results in degeneration of CA3 pyramidal cells but without apparent ultrastructural damage to mossy fibers as seen after intraventricular administration of the neurotoxin (Olney et al., 1979) . Our data support the finding that granule cells are intact and able to maintain cellular function at 6 hr postintraperitoneal administration of KA, and, in fact, increase the expression of BDNF mRNA and protein, as well as trkrunc mRNA. Additionally, pro-BDNF-IR was not detected in the neuropil or in mossy fiber terminal zones as noted for BDNF-IR.
Thus, alterations in BDNF-IR in the mossy fiber terminal zone reported in the present study cannot be explained solely by ultrastructural changes and degeneration of the mossy fibers, which may allow cellular contents to diffuse out of compromised membranes.
After kainate-induced damage to the hippocampal system, an enhancement of Timm's staining has been observed in this region and was correlated to extensive mossy fiber sprouting (Represa et al., 1987) and a "restructuring" of the mossy fiber projections (Nadler et al., 198 1) . Thus, an increased local availability of BDNF may support some of the cellular changes (e.g., sprouting, establishment of new synapses) observed after neuronal damage in experimental as well as in disease states (see Mattson, 1989; Sutula et al., 1989; Cavazos et al., 199 1; Patterson et al., 1992; see Ben-Ari and Represa, 1990) . Interestingly, expression of BDNF remains elevated in granule and pyramidal neurons of pentylenetetrazol-kindled rats for as long as 10 d after the last injection (Humpel et al., 1993) , indicating that the upregulation of BDNF expression may not simply be a response to acute stress.
The general trend in hippocampal areas CA2 and CA3 with respect to BDNF-IR was one of a dramatic and marked shift or "release" into the surrounding parenchyma, accompanied by a decrease in intracellular BDNF-IR (seen throughout all hippocampal areas). Subsequently, cellular BDNF-IR increased above control levels and, in some cases, was accompanied by cell death throughout hippocampal areas (CA3 and hilus) with marked sparing of CA2. Six hours after KA exposure, the levels of BDNF-IR were dramatically increased in pyramidal cells in CA2 and scattered throughout CA 1 and CA3, with a particularly strong immunolabeling in CA3 pyramidal cells, known to be 3 orders of magnitude more sensitive to KA than neurons in CA1 (Robertson and Deadwyler, 1981) . The different spatial and temporal modulation of BDNF-IR is consistent with regional alterations in BDNF mRNA and with the known distribution of kainate binding sites (Monaghan et al., 1983) .
The dramatic increase of BDNF-IR in the neuropil and surrounding tissue in CA3 areas is especially interesting with respect to implications that this shift of the protein localization has for the release and action of BDNF in the unperturbed nervous system. While decreased levels of NGF protein have been reported in the hippocampus and septum after a partial reduction in tonic glutamate activity by NMDA receptor blockade (Zafra et al., 1991) , it has not been demonstrated whether this blockade directly interferes with protein release or, moreover, whether neurotrophins are released from neurons via regulated and/or constitutive pathways. It has been demonstrated that neuropeptides are transported in regulated secretory pathways and are difficult to detect in neuronal perikarya without experimental manipulation, yet are readily detected in areas of comparatively higher concentration such as axon terminals (Elde et al., 1978) . In contrast, it appears that BDNF-IR is more readily detected in somatic compartments, and has not yet been detected in axons (Wetmore et al., 199 1) . Our data indicate that after excitatory amino acid stimulation, BDNF-IR can be released from somatic and/or dendritic sites and appears not to be confined to release from sites at axon terminals, which is suggestive of constitutive release. One may also speculate that such a shift in BDNF-IR from cells to the surrounding parenchyma may simply be further evidence of cellular damage and is a result of compromised neuronal membranes, allowing the cytoplasmic contents to spill into the surrounding tissue. However, the apparent shift in localization of BDNF-IR is detected 2-3 hr after KA exposure, at a time when expression of BDNF mRNA has yet to peak (Dugich-Djordjevic et al., 1992 ; C. Wetmore and A. J. Bean, unpublished observations), suggest that the neurons are, in fact, maintaining metabolic function and activity at a rate higher than basal levels, which could not be occurring if the cell membranes were sufficiently compromised to allow the diffusion of a protein the size of BDNF out of the neuron, BDNF mRNA levels remain elevated for several days et al. * Cel l ul ar Recognition of BDNF Expression in dentate and hilar areas of hippocampus (Dugich-Djordjevic et al., 1992) . Additionally, while an increase in pro-BDNF-IR was also detected within the perikarya of pyramidal and granule cells, pro-BDNF-IR was not localized to any extracellular or neuropil compartments, suggesting that pro-BDNF is not released from the neuron rounding parenchyma may be relevant to the maintenance of synaptic plasticity and, in particular, may play a critical role in supporting the sprouting of collateral mossy fibers as has been reported to occur after KA lesion (Cotman et al., 1984; Cotman, It is interesting to note that, in addition to established sites of BDNF transcription and translation, there also exist sites of possible BDNF action in hippocampal and other cortical areas, as demonstrated by the localization of mRNA for various transcripts of trkB (Fig. 2) , the putative BDNF receptor (Soppet et al., 199 1; Squint0 et al., 199 1) . Several transcripts of trkB have been reported; however, only the full-length transcript encodes an intracellular tyrosine kinase domain that appears necessary for transducing intracellular biological response (Klein et al., 1990; Middlemas et al., 199 1) . The present study indicates that the full-length trkB transcript is confined to neuronal sites of expression, while truncated (i.e., not containing the tyrosine kinase domain) forms of trkB mRNA are also expressed by glial cells (Fig. 2B) . Preliminary evidence suggests that cellular levels of expression of truncated forms of trkB are increased after systemic KA exposure, while the expression of full-length trkB transcript is not (Wetmore and Bean, unpublished observations) . A similar upregulation of trkB mRNA has been reported in scar tissue in the spinal cord after lesion ofthe dorsal funiculus (FrisCn et al., 1992) . These data provide an interesting basis for speculation on the possibility of different physiological roles for trkB and trkB,,,,, in damaged neuronal tissues. Specifically, it may be that the truncated forms of trkB, which lack the intracellular, signal-transducing, tyrosine kinase domain, are inserted into the membrane and act as extracellular binding proteins, which serve to "anchor" ambient BDNF to the cell membrane and thereby establish a concentrated source or gradient of BDNF supportive of local fiber outgrowth, analogous to that which has been suggested for the low-affinity NGF receptor in Schwann cells (Taniuchi et al., 1986) . The release of BDNF into surand temporal lobe epilepsy. The capability for modulation of trophic factor levels by endogenous transmitter systems may provide a physiologic mechanism for maintaining plasticity in the CNS.
1985; Represa et al., 1987) .
In conclusion, we provide evidence from in vivo studies at the cellular level for the regulation of BDNF mRNA and protein via kainate but not NMDA receptors. Significant alterations in the cellular compartmentalization of BDNF-IR were detected in hippocampal and, to a lesser degree, other cortical areas after KA exposure. The modulation of neurotrophin expression and protein levels in restricted subpopulations of neurons by neuronal activity suggests that neurotrophins may be involved in CNS function in a capacity beyond trophic maintenance of connections, that is, in cell homeostasis and in a possible type of "protection" when cells are subjected to supraphysiologic stress such as seizures or in neurodegenerative disease. The present study localized mRNA for two forms of the putative BDNF receptor, trkB, to an overlapping population of neurons that also appear to have the capability to transcribe and translate an endogenous ligand for this receptor, BDNF. These data suggest the possibility for local mechanisms of BDNF release from the dendrites and/or somata and provide evidence of receptor components necessary for biologically relevant response to this neurotrophin, which are of particular importance in the trophic support of sprouting and synaptic changes described in kindling Cotman CW, Monaghan DT, Ottersen OP, Storm-Mathisen J (1987) Anatomical organization 
